Glutarate

Glutarate

SCHEMBL3688894

O=C([O-])CCCC(=O)[O-].[Mn+2]

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.58
▸ HDAC3 O15379 3/20 0.50
▸ HDAC1 Q13547 3/20 0.50
▸ HDAC2 Q92769 3/20 0.50
▸ HDAC8 Q9BY41 3/20 0.50
▸ FFAR3 O14843 2/20 0.50
▸ BBOX1 O75936 3/20 0.46
▸ CA4 P22748 2/20 0.44
▸ FABP3 P05413 2/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ SLC22A6 Q4U2R8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutarate SCHEMBL3142978 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL1035895 0.92 — —
Glutarate SCHEMBL5134529 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL1533372 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL4520000 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL3686349 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL162951 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL104914 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL3687196 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8
Glutarate SCHEMBL1740443 0.92 CA1 (0.58) CA1HDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305273-B1 METHOD FOR OXIDISING HYDROCARBONS, ALCOHOLS AND/OR KETONES RHODIA POLYAMIDE INTERMEDIATES (FR) 2005-04-27 — — EP claimed
US-6762319-B1 Hydrocarbon, alcohol and/or ketone oxidation method RHODIA POLYAMIDE INTERMEDIATES (FR) 2004-07-13 — — US claimed
EP-1165481-B1 PROCESS FOR THE OXIDATION OF CYCLOALKANES, CYCLOALCOHOLS AND/OR CYCLOKETONES RHODIA POLYAMIDE INTERMEDIATES (FR) 2003-09-17 — — EP claimed
US-11968978-B2 Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations INNOVATION HAMMER LLC (US) 2024-04-30 — — US disclosed
EP-4218414-A1 FORMULATIONS AND METHODS FOR TREATING PHOTOSYNTHETIC ORGANISMS AND ENHANCING QUALITIES AND QUANTITIES OF YIELDS WITH GLYCAN COMPOSITE FORMULATIONS Innovation Hammer LLC (US) 2023-08-02 — — EP disclosed
US-11122804-B2 Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations INNOVATION HAMMER LLC (US) 2021-09-21 — — US disclosed
US-11013234-B2 Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations INNOVATION HAMMER LLC (US) 2021-05-25 — — US disclosed
US-20200404912-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations INNOVATION HAMMER LLC (US) 2020-12-31 — — US disclosed
US-20200404913-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations INNOVATION HAMMER LLC (US) 2020-12-31 — — US disclosed
US-20200060274-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations INNOVATION HAMMER LLC (US) 2020-02-27 — — US disclosed
US-20170311598-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations INNOVATION HAMMER LLC 2017-11-02 — — US disclosed
US-20140150868-A1 PHOTOELECTRIC CONVERSION ELEMENT AND MANUFACTURING METHOD THEREOF JX NIPPON OIL & ENERGY CORPORATION (JP) 2014-06-05 — — US disclosed
US-7705179-B2 Method for oxidising hydrocarbons, alcohols and/or ketones RHODIA POLYAMIDE INTERMEDIATES (FR) 2010-04-27 — — US disclosed
US-20080015299-A1 Acicular boehmite and process for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED 2008-01-17 — — US disclosed
US-20070227399-A1 COMPOSITIONS AND METHODS FOR THE PRESERVATION OF WOOD NOVUS INTERNATIONAL INC. (US) 2007-10-04 — — US disclosed
US-20050277787-A1 oxidizing a compound selected from cycloalkane, cycloalkanol and cycloalkanone, with oxygen in a liquid phase and in the presence of a catalyst dissolved in the reaction medium characterized in that the catalyst containing at least one soluble Mn and/or Co compound, soluble Cr and Fe compounds PHODIA POLYAMIDE INTERMEDIATES (FR) 2005-12-15 — — US disclosed
EP-1533273-A1 Aluminium hydroxide, aluminium hydroxide slurry and resin composition containing the same, and method for producing the same Sumitomo Chemical Company, Limited (JP) 2005-05-25 — — EP disclosed
US-20050090595-A1 Aluminum hydroxide, aluminum hydroxide slurry and resin composition containing the same, and method for producing the same SUMITOMO CHEMICAL COMPANY, LIMITED 2005-04-28 — — US disclosed
US-6762319-B1 Hydrocarbon, alcohol and/or ketone oxidation method RHODIA POLYAMIDE INTERMEDIATES (FR) 2004-07-13 — — US disclosed
EP-0558311-A1 Light-sensitive lithographic printing plate KONICA CORPORATION (JP) 1993-09-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11013234-B2 Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations GMDS, AGL, ALG1 CA1 3749/4885HDAC3 2110/4885HDAC1 3232/4885
US-20200404913-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations GMDS, AGL, ALG1 CA1 3749/4885HDAC3 2110/4885HDAC1 3232/4885
US-20200404912-A1 Formulations And Methods For Treating Photosynthetic Organisms And Enhancing Qualities And Quantities Of Yields With Glycan Composite Formulations GMDS, AGL, ALG1 CA1 3749/4885HDAC3 2110/4885HDAC1 3232/4885
US-11968978-B2 Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations GMDS, AGL, ALG1 CA1 3749/4885HDAC3 2110/4885HDAC1 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback